A Controlled Trial of a Formalin-Inactivated Hepatitis A Vaccine in Healthy Children

New England Journal of Medicine

Volumn 327, Issue 7, 1992, Pages 453-457

  Werzberger, Alan ^a   Mensch, Barbara ^a   Kuter, Barbara ^c   Brown, Leora ^c   Lewis, John ^c   Sitrin, Robert ^c   Miller, William ^c   Shouval, Daniel ^b   Wiens, Brian ^c   Calandra, Gary ^c   Ryan, John ^c   Provost, Philip ^c   Nalin, David ^c  

^a Kiryas Joel Medical Research Institute Inc   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FORMALDEHYDE; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; IMMUNOGLOBULIN M; INACTIVATED VIRUS VACCINE;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS A; HUMAN; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROLOGY; VIRUS IMMUNITY;

ADOLESCENT; ALANINE TRANSAMINASE; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FORMALDEHYDE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS ANTIBODIES; HEPATOVIRUS; HUMAN; IMMUNOGLOBULIN M; SUPPORT, NON-U.S. GOV'T; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 0026643021     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199208133270702     Document Type: Article

References (21)

1. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: contemporary issues and future prospects. Baltimore: Williams & Wilkins, 1991:14–20.
2. Conrad ME, Lemon SM. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis 1987; 156: 56–63.
3. Krah DL, Amin RD, Nalin DR, Provost PJ. A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus. J Infect Dis 1991; 163: 634–7.
4. Shouval D, Ashur Y, Adler R, et al. Comparison of immune serum globulin (ISG) with a formalin inactivated, alum adjuvanted hepatitis A vaccine. Presented at the Fifth European Congress of Clinical Microbiology and Infectious Diseases, Oslo, Norway, September 9–11, 1991. abstract.
5. Provost PJ, Hilleman MR. An inactivated hepatitis A virus vaccine prepared from infected marmoset liver. Proc Soc Exp Biol Med 1978; 159: 201–3.
6. Provost. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 1979; 160: 213–21.
7. Provost PJ, Conti PA, Giesa PA, et al. Studies in chimpanzees of live, attenuated hepatitis A vaccine candidates. Proc Soc Exp Biol Med 1983; 172: 357–63.
8. Provost PJ, Bishop RP, Gerety RJ, et al. New findings in live, attenuated hepatitis A vaccine development. J Med Virol 1986; 20: 165–75.
9. Provost PJ, Hughes JV, Miller WJ, Giesa PA, Banker FS, Emini EA. An inactivated hepatitis A viral vaccine of cell culture origin. J Med Virol 1986; 19: 23–31.
10. Purcell RH. Approaches to immunization against hepatitis virus. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: contemporary issues and future prospects. Baltimore: Williams & Wilkins, 1991:41–6.
11. Midthun K, Ellerbeck E, Gershman K, et al. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis 1991; 163: 735–9.
12. Lewis JA, Armstrong ME, Larson VM, et al. Use of a live, attenuated hepatitis A vaccine to prepare a highly purified, formalin-inactivated hepatitis A vaccine. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: contemporary issues and future prospects. Baltimore: Williams & Wilkins, 1991:94–7.
13. Ellerbeck E, Lewis J, Midthun K, et al. Safety and immunogenicity of an inactivated hepatitis A virus vaccine: inactivated hepatitis A vaccine. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: contemporary issues and future prospects. Baltimore: Williams & Wilkins, 1991:91–3.
14. Nalin DR, Calandra G, Ryan J, et al. Experience with an inactivated hepatitis A vaccine. Am J Trop Med Hyg 1991; 45: Suppl: 218.
15. Kuter B, Bishop R, Falcone R, et al. Safety and immunogenicity of inactivated hepatitis A vaccine in healthy adults. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29—October 2, 1991. Washington, DC.: American Society for Microbiology, 1991:282. abstract.
16. Block S, Hedrick J, Tyler R, et al. Safety, tolerability and immunogenicity of a formalin inactivated hepatitis A vaccine in children ages 4–12 years. In: Program and abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29—October 2, 1991. Washington, D.C.: American Society for Microbiology, 1991:314. abstract.
17. Smith PF, Grabau JC, Werzberger A, Kondraki SF, Gallo RJ, Morse DL. Hepatitis A in a Hasidic Jewish community, upstate New York. Presented at the Epidemic Intelligence Service 35th Annual Conference, Centers for Disease Control, Atlanta, April 14–18, 1986. abstract.
18. Ward R, Krugman S, Giles JP, Jacobs AM, Bodansky O. Infectious hepatitis: studies of its natural history and prevention. N Engl J Med 1958; 258: 407–16.
19. Lemon SM, Ping L, Day S, et al. Immunobiology of hepatitis A virus. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: contemporary issues and future prospects. Baltimore: Williams & Wilkins, 1991:20–5.
20. Robertson BH, Khanna B, Nainan OV, Margolis HS. Epidemiologic patterns of wild-type hepatitis A virus determined by genetic variation. J Infect Dis 1991; 163: 286–92.
21. Villarejos VM, Serra JC, Anderson-Visona K, Mosley JW. Hepatitis A virus infection in households. Am J Epidemiol 1982; 115: 577–86.